Premium
Five‐day regimens containing ranitidine bismuth citrate plus high‐dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection
Author(s) -
Giovanni Cammarota,
O Cannizzaro,
Veronica Ojetti,
Rossella Cianci,
Alfredo Pastorelli,
Alessandro Armuzzi,
N Gentiloni,
Antonio Gasbarrini,
Giuseppe Pirozzi,
Giovanni Gasbarrini
Publication year - 2000
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2000.00664.x
Subject(s) - tinidazole , medicine , clarithromycin , helicobacter pylori , gastroenterology , rapid urease test , amoxicillin , ranitidine hydrochloride , breath test , group b , urea breath test , ranitidine , metronidazole , antibiotics , gastritis , helicobacter pylori infection , microbiology and biotechnology , biology
Background: Ranitidine bismuth citrate (RBC)‐based triple therapies for a period of 7 days have proved to be an effective treatment for Helicobacter pylori . Aim: To investigate the eradication efficacy, safety profile and patient compliance of two RBC‐based triple therapies given for 5 days. Methods: Eighty H. pylori ‐positive patients with dyspeptic symptoms, referred to us for gastroscopy, were consecutively enrolled in this prospective, randomized, open‐label study. These patients were randomly assigned to receive a 5‐day course of RBC 400 mg b.d. plus clarithromycin 500 mg b.d. and either tinidazole 500 mg b.d. (RBCCT group) or amoxycillin 1 g b.d. (RBCCA group). The H. pylori status was assessed by means of histology and rapid urease test at entry, and by 13 C‐urea breath test 8 weeks after the completion of treatment. Results: All enrolled patients completed the study. Thirty‐seven of 40 patients treated with RBCCT (both PP and ITT analysis: 93%; 95% CI: 80–98%) and 35 of 40 in the RBCCA group (both PP and ITT analysis: 88%; 95% CI: 73–96%) returned H. pylori ‐negative. Slight or mild side‐effects occurred in 4/40 patients (10%) in the RBCCT group and in 5/40 (12%) in the RBCCA group. Conclusions: This is the first study demonstrating the efficacy of RBC‐based triple therapies given for only 5 days. RBC regimens containing high‐dose clarithromycin and either amoxycillin or tinidazole prove to be well tolerated, safe and preserve good eradication rates even when administered for a shorter than conventional duration.